SAN DIEGO, May 05, 2010 (BUSINESS WIRE) —ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical companyutilizing innovative technology to fuel drug discovery and clinicaldevelopment of novel treatments for central nervous system disorders,today announced that it will present at the Ninth Annual JMP SecuritiesResearch Conference on Wednesday, May 12, 2010 at 11:00 a.m. PacificTime at The Ritz-Carlton Hotel in San Francisco.
A live webcast of ACADIA's presentation will be accessible on thecompany's website, www.acadia-pharm.com,under the investors section and an archived recording will be availableon the website through May 26, 2010.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company utilizing innovative technology tofuel drug discovery and clinical development of novel treatments forcentral nervous system disorders. ACADIA is currently developing aportfolio consisting of four product candidates including pimavanserin,which is being developed for three separate neurological and psychiatricindications in collaboration with Biovail. These indications areParkinson's disease psychosis, which is in Phase III development,co-therapy for schizophrenia, which is in Phase III planning, andAlzheimer's disease psychosis, for which ACADIA is planning to initiatea Phase II feasibility study. In addition to pimavanserin, ACADIA has aproduct candidate in Phase II for chronic pain and a product candidatein Phase I for glaucoma, both in collaboration with Allergan, as well asa product candidate for schizophrenia in IND-track development incollaboration with Meiji Seika Kaisha. All of the product candidates inACADIA's pipeline emanate from discoveries made using its proprietarydrug discovery platform. ACADIA maintains a website at www.acadia-pharm.comto which ACADIA regularly posts copies of its press releases as well asadditional information and through which interested parties cansubscribe to receive email alerts.
Forward-Looking Statements
Statements in this press release that are not strictly historical innature are forward-looking statements. These statements include but arenot limited to statements related to the progress and timing of ACADIA'sdrug discovery and development programs either alone or with a partner,including clinical trials, and the benefits to be derived from ACADIA'sproduct candidates, in each case including pimavanserin. Thesestatements are only predictions based on current information andexpectations and involve a number of risks and uncertainties. Actualevents or results may differ materially from those projected in any ofsuch statements due to various factors, including the risks anduncertainties inherent in drug discovery, development andcommercialization, and collaborations with others, and the fact thatpast results of clinical trials may not be indicative of future trialresults. For a discussion of these and other factors, please refer toACADIA's annual report on Form 10-K for the year ended December 31, 2009as well as other subsequent filings with the Securities and ExchangeCommission. You are cautioned not to place undue reliance on theseforward-looking statements, which speak only as of the date hereof. Thiscaution is made under the safe harbor provisions of the PrivateSecurities Litigation Reform Act of 1995. All forward-looking statementsare qualified in their entirety by this cautionary statement and ACADIAundertakes no obligation to revise or update this press release toreflect events or circumstances after the date hereof.
SOURCE: ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc.
Thomas H. Aasen, Executive Vice President,
Chief Financial Officer and Chief Business Officer
858-558-2871